A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies.

Mark A Dawson Gautam Borthakur Brian James Patrick Huntly Anastasios Karadimitris Adrian Alegre Aristeidis Chaidos Dan T Vogl Daniel A Pollyea Faith E Davies Gareth J Morgan Jacob Lowell Glass Manali Kamdar Maria-Victoria Mateos-Manteca Natalia Tovar Paul Yeh Regina García Delgado Faisal Basheer Ludovica Marando Paolo Gallipoli Anastasia Wyce Anu Shilpa Krishnatry Olena Barbash Evi Bakirtzi Geraldine Ferron-Brady Natalie O Karpinich Michael T McCabe Shawn W Foley Thierry Horner Arindam Dhar Brandon E Kremer Michael J Dickinson

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

While anti-tumor activity was observed with molibresib, use was limited by gastrointestinal and thrombocytopenia toxicities. Investigations of molibresib as part of combination regimens may be warranted.

Keyphrases

open label
acute lymphoblastic leukemia
clinical trial
acute myeloid leukemia
diffuse large b cell lymphoma
hodgkin lymphoma
randomized controlled trial
radiation therapy
combination therapy
replacement therapy